Isolated Small Bowel Transplant

Policy Number: MM.07.022

Original Effective Date: 05/23/2001

Line(s) of Business: HMO; PPO

Current Effective Date: 04/28/2017

Section: Transplants

Place(s) of Service: Inpatient

Precertification is required for this service

I. Description

A small bowel transplant may be performed as an isolated procedure or in conjunction with other visceral organs, including the liver, duodenum, jejunum, ileum, pancreas, or colon. Isolated small bowel transplant is commonly performed in patients with short bowel syndrome.

For individuals who have intestinal failure who receive a small bowel transplant, the evidence includes case series. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. Small bowel transplant is infrequently performed, and only relatively small case series, generally single-center, are available. Risks after small bowel transplant are high, particularly related to infection, but may be balanced against the need to avoid the long-term complications of total parenteral nutrition dependence. In addition, early small bowel transplant may obviate the need for a later combined liver/small bowel transplant. Transplantation is contraindicated in patients in whom the procedure is expected to be futile due to comorbid disease or in whom posttransplantation care is expected to significantly worsen comorbid conditions. Guidelines and U.S. federal policy no longer view HIV infection as an absolute contraindication for solid organ transplantation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have failed small bowel transplant without contraindication(s) for retransplant who receive a small bowel retransplant, the evidence includes case series. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. Data from only a small number of patients undergoing retransplantation are available. Although limited in quantity, the available data after retransplantation have suggested a reasonably high survival rate after small bowel in patients who continue to meet criteria for transplantation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
Small bowel transplantation using a living donor may be considered medically necessary only when a cadaveric intestinal transplant is not available. The available published survival data have suggested that small bowel retransplant is a reasonable option after a failed primary small bowel transplant; thus, this may be considered medically necessary. Routine use of living-donor intestinal transplants is considered not medically necessary because the net health outcome associated with this procedure is reduced (compared with cadaveric transplant) due to donor-related morbidity.

Background

A small bowel transplant is typically performed in patients with short bowel syndrome. This is a condition in which the absorbing surface of the small intestine is inadequate due to extensive disease or surgical removal of a large portion of small intestine. In adults, etiologies of short bowel syndrome include ischemia, trauma, volvulus, and tumors. In children, gastroschisis, volvulus, necrotizing enterocolitis, and congenital atresias are predominant causes.

The small intestine, particularly the ileum, does have the capacity to adapt to some functions of the diseased or removed portion over a period of 1 to 2 years. Prognosis for recovery depends on the degree and location of small intestine damage. Therapy is focused on achieving adequate macro- and micro-nutrient uptake in the remaining small bowel. Pharmacologic agents have been studied to increase villous proliferation and slow transit times, and surgical techniques have been advocated to optimize remaining small bowel. However, some patients with short bowel syndrome are unable to obtain adequate nutrition from enteral feeding and become chronically dependent on total parenteral nutrition (TPN). Patients with complications from TPN may be considered candidates for small bowel transplant. Complications include catheter-related mechanical problems, infections, hepatobiliary disease, and metabolic bone disease. While cadaveric intestinal transplant is the most commonly performed transplant, there has been recent interest in using living donors.

Intestinal transplants (including multivisceral and bowel/liver) represent a small minority of all solid organ transplants. In 2011, 129 intestinal transplants were performed in the United States, of which all but 1 was from deceased donors. In 2012, 106 intestinal transplants were performed in the United States; all were from deceased donors.

II. Criteria/Guidelines

A. A small bowel transplant using cadaveric intestine is covered (subject to Limitations and Administrative Guidelines) in adult and pediatric patients with intestinal failure (characterized by loss of absorption and the inability to maintain protein-energy, fluid, electrolyte, or micronutrient balance), who have established long-term dependency on total parenteral nutrition (TPN) and are developing or have developed severe complications due to TPN.

B. A small bowel transplant using a living donor is covered (subject to Limitations and Administrative Guidelines) only when a cadaveric intestine is not available for transplantation in a patient who meets the criteria noted above for a cadaveric intestinal transplant.
C. A small bowel retransplant is covered (subject to Limitations and Administrative Guidelines) after a failed primary small bowel transplant.

D. Potential contraindications subject to the judgment of the transplant center:
   1. Known current malignancy, including metastatic cancer
   2. Recent malignancy with high risk of recurrence
   3. Untreated systemic infection making immunosuppression unsafe, including chronic infection
   4. Other irreversible end-stage disease not attributed to intestinal failure
   5. History of cancer with a moderate risk of recurrence
   6. Systemic disease that could be exacerbated by immunosuppression
   7. Psychosocial conditions or chemical dependency affecting ability to adhere to therapy

Small Bowel Specific
Intestinal failure results from surgical resection, congenital defect, or disease-associated loss of absorption and is characterized by the inability to maintain protein-energy, fluid, electrolyte, or micronutrient balance. Short-bowel syndrome is one case of intestinal failure.

Patients who are developing or have developed severe complications due to total parenteral nutrition (TPN) include, but are not limited to, the following: multiple and prolonged hospitalizations to treat TPN-related complications (especially repeated episodes of catheter-related sepsis) or the development of progressive liver failure. In the setting of progressive liver failure, small bowel transplant may be considered a technique to avoid end-stage liver failure related to chronic TPN, thus avoiding the necessity of a multivisceral transplant. In those receiving TPN, liver disease with jaundice (total bilirubin above 3 mg/dL) is often associated with development of irreversible progressive liver disease. The inability to maintain venous access is another reason to consider small bowel transplant in those who are dependent on TPN.

III. Limitations/Exclusions
   A. A small bowel transplant using living donors is not covered in all other situations as it is not known to be effective in improving health outcomes.
   B. A small bowel transplant is not covered for adults and pediatric patients with intestinal failure who are able to tolerate TPN as it is not known to be effective in improving health outcomes.

IV. Administrative Guidelines
   A. Precertification is required for a transplant evaluation and for the transplant itself and should be submitted by the proposed treating facility. To precertify, please complete HMSA's Precertification Request and mail or fax the form, or use iExchange as indicated along with the required documentation.
   B. Applicable codes:

<table>
<thead>
<tr>
<th>CPT Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>44132</td>
<td>Donor enterectomy (including cold preservation), open; from cadaver donor</td>
</tr>
</tbody>
</table>
Isolated Small Bowel Transplant

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>44133</td>
<td>Donor enterectomy (including cold preservation), open; partial, from <em>living</em> donor</td>
</tr>
<tr>
<td>44135</td>
<td>Intestinal allotransplantation; from <em>cadaver</em> donor</td>
</tr>
<tr>
<td>44136</td>
<td>Intestinal allotransplantation; from <em>living</em> donor</td>
</tr>
<tr>
<td>44715</td>
<td>Backbench standard preparation of cadaver or living donor intestine allograft prior to transplantation, including mobilization and fashioning of the superior mesenteric artery and vein</td>
</tr>
<tr>
<td>44720</td>
<td>Backbench reconstruction of cadaver or living donor intestine allograft prior to transplantation; venous anastomosis, each</td>
</tr>
<tr>
<td>44721</td>
<td>Backbench reconstruction of cadaver or living donor intestine allograft prior to transplantation; arterial anastomosis, each</td>
</tr>
</tbody>
</table>

ICD-10 codes are provided for your information.

<table>
<thead>
<tr>
<th>ICD-10-CM</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>K90.0-K90.9</td>
<td>Intestinal malabsorption code range</td>
</tr>
<tr>
<td>K91.2</td>
<td>Postsurgical malabsorption, not elsewhere classified</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0DY80Z0</td>
<td>Surgical, gastrointestinal system, transplantation, small intestine, open, allogeneic</td>
</tr>
</tbody>
</table>

V. Scientific Background

This policy has updated regularly with searches of the MEDLINE database. Most recently, the literature was reviewed through November 3, 2016.

**SMALL BOWEL TRANSPLANTATION**

This policy is based on 2 TEC Assessments conducted in the 1990s. The 1995 TEC Assessment concluded that in children, small bowel transplant was associated with improved survival compared to total parenteral nutrition (TPN) as the associated adverse outcomes for small bowel transplant were offset by severe TPN-related complications. This assessment also concluded that, in adults, the outcomes for small bowel transplant were worse than that associated with TPN. A 1999 TEC Assessment reevaluated the data on adults and concluded that it is not possible to predict which patients would survive longer on TPN versus small bowel transplant and therefore that transplantation is a reasonable option in selected adults.

Much of the published literature consists of relatively small case series. For example, in 2014, Ueno et al in Japan reported on 21 intestinal transplant patients; all but one received an isolated small bowel transplant for intestinal failure. The overall 1- and 5- year survival rates were 86% and 68%,
respectively. In the 15 patients who underwent transplantation after 2006, 1-year survival was 92% and 5-year survival was 83%.

These reports, as well as reviews of observational data, observe that while outcomes continue to improve, obstacles to long-term survival remain. Recurrent and chronic rejections and complications of immunosuppression are significant issues in bowel transplantation.

One issue in the literature is the importance of timely referral for intestinal transplantation to avoid the necessity of combined liver and intestine transplantation. It has been suggested that recent improvements in survival may justify removing the restriction of intestinal transplantation to patients who have severe complications of TPN. However, as noted by Vianna and colleagues in their 2008 report on the status of intestinal transplantation, no randomized trials compare intestinal transplantation to long-term parenteral nutrition, and optimal timing for earlier transplantation has not been established.

Another issue in the literature is the rate of various complications after small bowel transplant. Florescu and colleagues have published several articles retrospectively reviewing complications in a cohort of 98 pediatric patients. Twenty-one of these children (21.4%) had an isolated small bowel transplant; the remainder had combined transplants. A 2012 study reported that 68 of the 98 patients (69%) developed at least one episode of bloodstream infection. Among the patients with an isolated small bowel transplant, the median time to infection for those who became infected was 4.5 months (95% confidence interval [CI]: 2.4 - 6.7 months). Also in 2012, the researchers reported that 7 of 98 patients (7%) developed cytomegalovirus (CMV) disease; only 1 of these had an isolated small bowel transplant. In 2010, Florescu and colleagues reported that 25 of 98 cases reviewed (25.5%) developed at least one episode of fungal infection; Candida infection was most common. The mortality rate did not differ significantly between patients who did and did not develop a fungal infection (32.3% vs. 29.8%, respectively; p=0.46).

Several other series have reported on renal failure after intestinal transplantation. In 2013, a research group in France reported that 7 of 12 children who had an isolated small bowel transplant had renal function complications at some point after surgery. Prior to treatment, all of the patients had normal renal functioning. In 2014, Calvo Pulido in Spain reported on 21 adults who underwent intestinal transplantation; 17 were isolated small bowel transplants. Thirteen patients (62%) experienced renal failure; the etiology included high ileostomy output, immunosuppression, and medical treatment.

**Living donors**

Cadaveric intestines have been most commonly used, but recently there has been interest in using a portion of intestine harvested from a living, related donor. Potential advantages of a living donor include the ability to plan the transplantation electively and better antigen matching, leading to improved management of rejection. Small case reports have been published of 1 or 2 patients with different lengths of the ileum or jejunum. While there appear to be minimal complications to the donors, of the 6 cases reported, 5 recipients remain on TPN for at least part of their nutrition. One patient remains healthy and is off TPN.

Benedetti and colleagues (2006) reported outcomes from 4 children and 7 adults who underwent 12 living-related small bowel transplantations between 1998 and 2004. All donors were reported
to have had uneventful recovery following removal of up to 40% of the small intestine. The 3-year patient survival was 82%, with graft survival of 75%. Longer follow-up from the earlier cases was not reported. Gangemi and Benedetti published a literature review of living donor small bowel transplantation reports from 2003 to 2006; all of the reports listed Benedetti (et al.) as author. The authors comment that, “Due to the excellent result in modern series of deceased donor bowel transplantation, widespread use of the procedure [living donor] should not be recommended, in consideration of the potential risks to donor. Furthermore, few centers have acquired the necessary experience with the procedure.”

In June 2010, Sudan published a review of current literature on long-term outcomes after intestinal transplantation. In this paper, the author notes that intestinal transplantation has become standard therapy for patients with life-threatening complications from parenteral nutrition therapy. Data from current single-center series indicates a 1-year patient survival rate of 78-85% and a 5+ year survival rate of 56-61%. With respect to pediatric intestinal transplant patients, the majority achieve normal growth velocity at 2 years posttransplant. However, oral aversion is a common problem; tube feedings are necessary in 45% of children. Sudan also reports on parental surveys of quality of life in pediatric transplant patients in which intestinal transplant patients appear to have modestly improved quality of life compared to patients remaining on TPN and slightly worse than matched school-age controls without intestinal disease.

**HIV+ Transplant Recipients**

Transplants for recipients with HIV infection has long been controversial, due to the long-term prognosis for human immunodeficiency virus (HIV) positivity and the impact of immunosuppression on HIV disease. Although HIV-positive transplant recipients may be a research interest of some transplant centers, the minimal data regarding long-term outcome in these patients primarily consist of case reports and abstract presentations of liver and kidney recipients. Nevertheless, some transplant surgeons would argue that HIV positivity is no longer an absolute contraindication to transplant due to the advent of highly active antiretroviral therapy (HAART), which has markedly changed the natural history of the disease.

As of 2013, the United Network for Organ Sharing (UNOS) policy on HIV-positive transplant candidates states “A potential candidate for organ transplantation whose test for HIV is positive should not be excluded from candidacy for organ transplantation unless there is a documented contraindication to transplantation based on local policy.” (Policy 4, Identification of Transmissible Diseases in Organ Recipients).

In 2006, the British HIV Association and the British Transplantation Society Standards Committee published guidelines for kidney transplantation in patients with HIV disease. These criteria may be extrapolated to other organs.

The guidelines, which are similar to the UNOS guidelines, recommend that any patient with end-stage organ disease with a life expectancy of at least 5 years is considered appropriate for transplantation under the following conditions:
Isolated Small Bowel Transplant

- CD4 200 cells/micro liter for at least 6 months.
- Undetectable HIV viremia (<50 HIV-1 RNA copies/mL) for at least 6 months
- Demonstrable adherence and a stable HAART regimen for at least 6 months
- Absence of AIDS-defining illness following successful immune reconstitution after HAART.

**Section Summary: Small Bowel Transplantation**
Small bowel transplant is an infrequently performed, and only relatively small case series, generally single-center, are available. Risks after small bowel transplant are high, particularly related to infection, but may be balanced against the need to avoid the long-term complications of TPN dependence. In addition, early small bowel transplant may obviate the need for a later combined liver/small bowel transplant. Guidelines and U.S. federal policy no longer view HIV infection as an absolute contraindication for solid organ transplantation.

**SMALL BOWEL RETRANSPLANTATION**
Desai et al (2012) have published the most comprehensive reporting of outcomes after repeat small bowel transplant in the United States. They evaluated data in the UNOS database on patients who underwent small bowel transplants in the United States between October 1987 and August 2009. The investigators identified 41 repeat isolated small bowel transplants in adults and 28 in children. Thirty-nine of the adults (95%) and 27 (96%) of the children had a previous isolated small bowel transplant; the remaining patients had an initial combined small bowel and liver transplant.

Among adults, survival rates after retransplant were 80% after 1 year, 47% after 3 years and 29% after 5 years. Comparable survival rates for primary isolated small bowel transplant were 84% after 1 year, 67% after 3 years, and 54% after 5 years. Survival was significantly lower after repeat isolated small bowel transplant compared with primary isolated small bowel transplant (p=0.005).

Among children, patient survival was 81% after 1 year, 74% after 3 years, and 58% after 5 years. These rates did not differ significantly from rates after primary isolated small bowel transplant (85% after 1 year, 71% after 3 years, 64% after 5 years, respectively).

**Section Summary: Small Bowel Retransplantation**
Data from only a small number of patients undergoing retransplantation are available. Although limited in quantity, the available data after retransplantation have suggested reasonably high survival rates after small bowel in patients who continue to meet criteria for transplantation.

**SUMMARY OF EVIDENCE**
For individuals who have intestinal failure who receive a small bowel transplant, the evidence includes case series. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. Small bowel transplant is infrequently performed, and only relatively small case series, generally single-center, are available. Risks after small bowel transplant are high, particularly related to infection, but may be balanced against the need to avoid the long-term complications of total parenteral nutrition dependence. In addition, early small bowel transplant may obviate the need for a later combined liver/small bowel transplant. Transplantation is contraindicated in patients in whom the procedure is expected to be futile due to comorbid disease or in whom posttransplantation care is expected to significantly worsen comorbid conditions. Guidelines and U.S. federal policy no longer view HIV infection as an absolute contraindication for
solid organ transplantation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have failed small bowel transplant without contraindication(s) for retransplant who receive a small bowel retransplant, the evidence includes case series. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. Data from only a small number of patients undergoing retransplantation are available. Although limited in quantity, the available data after retransplantation have suggested a reasonably high survival rate after small bowel in patients who continue to meet criteria for transplantation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Clinical Input Received through Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received through 2 physician specialty societies and 2 academic medical centers while this policy was under review for July 2009. The consensus of those providing input was that small bowel transplant should be performed in patients who are developing severe TPN-related complications and that small bowel transplant from living donors may be considered when cadaveric intestinal transplants are not available.

Practice Guidelines, and Position Statements

In 2003, the American Gastroenterological Association produced a medical position statement on short bowel syndrome and intestinal transplantation. It recommends dietary, medical, and surgical solutions. Indications for intestinal transplantation mirror those of CMS. The guidelines acknowledge the limitations of transplant for these patients. The statement recommended the following Medicare-approved indications, pending availability of additional data:

1. “Impending or overt liver failure....
2. Thrombosis of major central venous channels....
3. Frequent central line-related sepsis....
4. Frequent severe dehydration.”

Medicare National Coverage

Effective for services performed on or after April 1, 2001, this procedure is covered only when performed for patients who have failed total parenteral nutrition (TPN) and only when performed in centers that meet approval criteria.

1. Failed TPN

The TPN delivers nutrients intravenously, avoiding the need for absorption through the small bowel. TPN failure includes the following:
Isolated Small Bowel Transplant

- Impending or overt liver failure due to TPN induced liver injury. The clinical manifestations include elevated serum bilirubin and/or liver enzymes, splenomegaly, thrombocytopenia, gastroesophageal varices, coagulopathy, stomal bleeding or hepatic fibrosis/cirrhosis.
- Thrombosis of the major central venous channels; jugular, subclavian, and femoral veins. Thrombosis of two or more of these vessels is considered a life-threatening complication and failure of TPN therapy. The sequelae of central venous thrombosis are lack of access for TPN infusion, fatal sepsis due to infected thrombi, pulmonary embolism, Superior Vena Cava syndrome, or chronic venous insufficiency.
- Frequent line infection and sepsis. The development of two or more episodes of systemic sepsis secondary to line infection per year that requires hospitalization indicates failure of TPN therapy. A single episode of line-related fungemia, septic shock and/or Acute Respiratory Distress Syndrome are considered indicators of TPN failure.
- Frequent episodes of severe dehydration despite intravenous fluid supplement in addition to TPN. Under certain medical conditions such as secretory diarrhea and nonconstructable gastrointestinal tract, the loss of the gastrointestinal and pancreatobiliary secretions exceeds the maximum intravenous infusion rates that can be tolerated by the cardiopulmonary system. Frequent episodes of dehydration are deleterious to all body organs particularly kidneys and the central nervous system with the development of multiple kidney stones, renal failure, and permanent brain damage.

2. Approved Transplant Facilities

Intestinal transplantation is covered by Medicare if performed in an approved facility. The criteria for approval of centers will be based on a volume of 10 intestinal transplants per year with a 1-year actuarial survival of 65 percent using the Kaplan-Meier technique.

REGULATORY STATUS

Small bowel transplantation is a surgical procedure and, as such, is not subject to regulation by the U.S. Food and Drug Administration.

ONGOING AND UNPUBLISHED CLINICAL TRIALS

A search of ClinicalTrials.gov in December 2016 did not identify any ongoing or unpublished trials that would likely influence this review.

VI. Important Reminder

The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician.

Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.
This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii’s Patients’ Bill of Rights and Responsibilities Act (Hawaii Revised Statutes §432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA’s determination as to medical necessity in a given case, the physician may request that HMSA reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation.

VII. References